U.S. Food and Drug Administration (FDA) scientists on June 13 said Pfizer’s COVID-19 vaccine performed well in young children, despite more vaccinated participants in Pfizer’s clinical trial experiencing severe illness than unvaccinated ones.
The data from the trial shows it is effective “in preventing COVID-19 in the age group of 6 months through 4 years,” FDA scientists said in a brief (pdf) filed with its vaccine advisory panel.
Additionally, the data “will likely have a beneficial effect” on hospitalization and death, the scientists alleged.
The FDA is signaling that it will grant the request for emergency use authorization from Pfizer and BioNTech, which made the vaccine together….